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With the sophistication of present day technology, we are
now able to deliver stereotactic ablative radiotherapy
(SABR), entailing delivery of ablative individual doses in
a very precise and accurate fashion to extracranial
tumours, a feat which was unimaginable in the past.
SABR is virtually a spin-off of intra-cranial stereotactic
radiosurgery (SRS) and has been used to treat primary
tumours of the lung, the liver, the kidney, and the
prostate, and oligometastatic and oligoprogressive
disease.1–3 In order to minimise any collateral damage to
surrounding normal parallel tissues like lung and liver or
adjacent serial organs such as the oesophagus or spinal
cord, highly conformal radiation isodose distribution and
very tight margins are used. For tumours that move with
respiration, manoeuvres accounting for respiratory
motion are necessary to avoid inadequate coverage of the
tumour being treated. To facilitate safe and effective
delivery of SABR, the technical requirements are very
stringent and their importance cannot be
overemphasised.
The SABR process can be divided into: (1) Proper
selection of patients; (2) Immobilisation; (3) Respiratory
motion control; (4) CT simulation; (5) Delineation of
target volume and organs-at-risk (OARs); (6) Treatment
planning; (7) Pre-treatment verification; and (8)
Treatment delivery and intra-fractional monitoring.1–3
The subsequent sections will discuss all the above
components individually.
Proper Patient Selection
Eligibility criteria vary among different trials or centres
for each disease site or condition.1 However, there are
some general stipulations to be met in order for the
patient to be eligible for SABR. Firstly, the patient must
be able to derive benefit from the procedure either in
terms of durable control of the target tumour or
symptomatic relief. In other words, there must be a set
goal for therapy for the patient. Secondly, the patient
must be able to tolerate lying still in the immobilisation
device for the SABR treatment. If a robotic radiosurgery
system is used, the treatment delivery time can easily
exceed 1 hour. However, if a linear accelerator (LINAC)-
based system is used and when volumetric modulated arc
therapy (VMAT) and beam-flattening filter-free feature
are available, the treatment delivery time can be
dramatically reduced. Thirdly, the target to be treated
must be clearly visualised on imaging as typically, there is
very little or no margin expansion around the gross
tumour volume (GTV) with SABR.
Immobilisation and Respiratory
Motion Control
A robust immobilisation is of utmost importance in the
SABR process as very tight margins are set around the
GTV and in many cases, such as in spinal metastasis,
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there are critical OARs in the proximity. Immobilisation
can be achieved either by the use of rigid external
immobilisation devices, by active motion detection and
compensation during treatment delivery and by fast
treatment delivery. Depending on the treatment machine
used and the body site to be treated, different
immobilisation devices should be considered.1–3 Among
all, spinal SABR requires the most robust immobilisation,
especially when a LINAC-based system is used. Li et al.
has demonstrated that the dual vacuum system (BodyFIX;
Elekta AB) is superior to other immobilisation devices in
terms of set-up accuracy and can keep the set-up
variation to 2 mm or less with intra-fractional
adjustment.4 However, colleagues from VU University
Medical Center in the Netherlands showed that based on
pre- and post-fraction X-ray imaging during fast lung
SABR, simple support devices can result in spine stability
that is comparable to that reported with rigid external
immobilisation.5 When a robotic radiosurgery system is
used, the near real-time tracking capability renders semi-
rigid immobilisation unnecessary and the patient can
simply be immobilised using a regular vacuum cushion
or body cradle.
With regard to respiratory motion control, there are 3
broad strategies, namely, motion dampening, gating, and
tracking.1 The 2 most common ways of achieving
motion dampening are abdominal compression and
active breathing coordination (ABC). The abdominal
compression device is frequently a built-in feature of
some commercially available stereotactic bodyframes.
The patient needs to be able to tolerate tight abdominal
compression and it is important to check to ascertain
that the patient does not have an abdominal aortic
aneurysm, which is at risk for rupture with application
of pressure. Gating entails tracking of the tumour’s
range of motion during respiratory cycles and the
radiation beam is switched on only during a specific
segment of each cycle. Tracking involves the moving of
the radiation beam in a near real-time fashion based on
the respiratory motion of the tumour utilising surrogate
markers such as fiducials. When none of the above
approaches are used, an internal target volume (ITV)
can be constructed based on a 4-dimensional CT
(4DCT) to account for the tumour position in all
respiratory phases.
Regardless of the manoeuvres used to account for
respiratory motion, the acquisition of treatment planning
data should incorporate the same considerations. All
breathing motion compensation strategies above are in
clinical routine use and have achieved excellent outcome.
To date, no study was able to confirm superiority of one
particular strategy over the others.
CT Simulation and Delineation of
Target Volume and Organs-at-Risk
(OARs)
Patients are immobilised in a reproducible setup for CT
simulation. Contrast injection can enhance the
visualisation of the gross tumour and facilitate
delineation of OARs, especially those close to vascular
structures. In many centres, when contrast injection is
planned, another set of non-contrast CT is done for
treatment planning in order to eliminate any uncertainty
in dose computation caused by the contrast. Depending
on the method of respiratory motion control, a free
breathing or a deep expiration CT can be used as the
primary image set for treatment planning. If fiducial
markers are used, the deep expiration CT will be more
suitable as the primary image set as the image of the
markers will be blurred out in a free breathing CT,
render tracking or gating based on the markers very
difficult. The slice thickness should be no greater than 1–
3 mm. For the treatment of tumours that move with
respiration, a 4DCT is obtained and fused with the
primary CT set regardless of the method of respiratory
control used. A maximum intensity projection can be
used to generate an ITV. Sometimes, for liver tumours
that are hypodense on CT, a minimum intensity
projection may be more useful than a maximum intensity
projection for ITV generation.
Other imaging modalities can be fused to the treatment
planning CT to assist in delineation of the target volume
and OARs. A positron emission tomography (PET) fused
with the treatment planning CT can be very useful for
lung, liver and adrenal tumours. For tumours (such as
liver, spinal and prostate tumours) or OARs (such as
spinal cord) not very well visualised on CT, the fusion of
appropriate sequences of magnetic resonance imaging
(MRI) with treatment planning CT can facilitate more
accurate target volume and OAR delineation. A CT
myelogram can be fused with the treatment planning CT
to facilitate delineation of the spinal cord in the scenario
where the artifacts from metallic spinal hardware obscure
the visualisation of the contents of the spinal canal.
Contouring atlases for OARs are available through the
Radiation Therapy Oncology Group (RTOG) website
(https://www.rtog.org/CoreLab/ContouringAtlases.aspx).
Treatment Planning
The treatment planning techniques commonly used for
LINAC-based SABR include 3-dimensional conformal
radiotherapy (3DCRT), intensity modulated radiotherapy
(IMRT), and VMAT. Fitzgerald et al. reported their
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experience with 3DCRT and VMAT at this journal
issue.6,7 The CyberKnife (Accuray, Sunnyvale, CA) system
has a unique treatment planning system based on
robotically directed beam delivery. If the tumour is in a
location where there are no critical OARs, an attempt is
usually made to create an isotropic isodose distribution.
On the other hand, when the tumour is in close
proximity to a critical OAR such the spinal cord as in
spinal metastasis, great efforts are made to steer the
radiation dose away from the structure utilising inverse
planning to avoid catastrophic toxicities.
The importance of the use of an optimal treatment
planning algorithm, particularly in the thoracic region,
cannot be overemphasised. Multiple studies have
demonstrated that the use of a suboptimal treatment
planning algorithm will result in inaccurate dose
estimation that can lead to inadequate tumour coverage.8
The Imaging and Radiation Oncology Core (IROC) at
M.D. Anderson Cancer Center has included a list of
approved treatment planning algorithms for lung targets
and they are approved for use in RTOG SABR trials
for lung tumours (http://rpc.mdanderson.org/RPC/home.
htm). A recent study based on data obtained from
anthropomorphic thorax phantom for RTOG credentialing
showed that even with advanced treatment planning
algorithms such as convolution/superposition and
anisotropic analytic algorithm (AAA), the dose that was
delivered to the lung target was overestimated. Only Monte
Carlo algorithm agreed with measurement within 0.6%.8
OAR constraints have been established in prospective trials
and developed in single-institutional studies, facilitating
safe delivery of SABR. However, prospective validation of
these tolerance doses is needed in the future.
Pre-treatment Verification, Treatment
Delivery and Intra-fractional
Monitoring
Before SABR is delivered, the pretreatment verification of
set-up accuracy is paramount. In the early days of
technical development, orthogonal ports were used. At
present, with the availability of advanced on-board
imaging technologies, stereoscopic X-rays, conebeam CT
(CBCT) or megavoltage (MV) CT (as used in Helical
TomoTherapy; Accuray) can be used to verify the set-up
with higher degree of set-up certainty.1 All in-room
verification imaging technologies need to be consistent
with treatment planning imaging regarding breathing
motion compensation.The mode of treatment delivery
depends on the treatment machine being used. In general,
a modern LINAC-based system takes a much shorter time
than a robotic radiosurgery system (CyberKnife; Accuray)
for radiation delivery. To ensure that the patient remains
in the same position during radiation delivery, a midway
CBCT or megavoltage CT (MVCT) can be performed and
adjustments can be made if the patient’s position
changes.1 The combination of digital tomosynthesis and
triangulation also allows for monitoring of spine position
with sub-mm accuracy and precision.9 The CyberKnife
system tracks the tumour or target using bony landmarks
or fiducial markers in a near real-time fashion
throughout the treatment.
Conclusion
SABR adds to the armamentarium against cancer and is a
very exciting therapeutic opportunity for cancer patients.
Its technical requirements have to be very stringent as the
therapeutic margin is narrow. When all the principles are
followed, it is possible to deliver SABR to extracranial
tumours safely and effectively. Further development of
SABR across the globe is under way and the expansion of
its applications in various oncological settings is
anticipated.
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